ArticlePLoS computational biology2012
Chapter 7: Pharmacogenomics.
Article in PLoS computational biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Pharmacological Approaches and Innovative Strategies for Individualized Patient Care.Recent patents on biotechnology · 2026Review
- Probing the binding hypothesis of Smad3 modulators by molecular dynamic simulations for Atherosclerosis Cardiovascular Disease (ASCVD).PloS one · 2025Article
- How data science and AI-based technologies impact genomics.Singapore medical journal · 2023Review
- MedGCN: Medication recommendation and lab test imputation via graph convolutional networks.Journal of biomedical informatics · 2022Article
- Recent Advances in Cancer Drug Discovery Through the Use of Phenotypic Reporter Systems, Connectivity Mapping, and Pooled CRISPR Screening.Frontiers in pharmacology · 2022Review
- Pharmacometabolomics by NMR in Oncology: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Identification of disease treatment mechanisms through the multiscale interactome.Nature communications · 2021Article
- Linking Pharmacogenomic Information on Drug Safety and Efficacy with Ethnic Minority Populations.Pharmaceutics · 2020Article
- Oncology and Pharmacogenomics Insights in Polycystic Ovary Syndrome: An Integrative Analysis.Frontiers in endocrinology · 2020Review
- Article
- Pharmacogenomics in dermatology: tools for understanding gene-drug associations.Seminars in cutaneous medicine and surgery · 2019Review
- Use of Pharmacogenetic Drugs by the Dutch Population.Frontiers in genetics · 2019Article
- PharmGKB: A worldwide resource for pharmacogenomic information.Wiley interdisciplinary reviews. Systems biology and medicine · 2018Review
- Pharmacogenomics and big genomic data: from lab to clinic and back again.Human molecular genetics · 2018Review
- Pharmacogenetics: An Important Part of Drug Development with A Focus on Its Application.International journal of biomedical investigation · 2018Article
- System pharmacogenomics application in infectious diseases.Briefings in functional genomics · 2017Review
- Toward precision medicine of breast cancer.Theoretical biology & medical modelling · 2016Review
- LightSNiP assay is a good strategy for pharmacogenetics test.Frontiers in pharmacology · 2015Article
- Adverse Drug Event-based Stratification of Tumor Mutations: A Case Study of Breast Cancer Patients Receiving Aromatase Inhibitors.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2014Article
- Concept of pharmacogenomics and future considerations.CNS neuroscience & therapeutics · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
There is great variation in drug-response phenotypes, and a "one size fits all" paradigm for drug delivery is flawed. Pharmacogenomics is the study of how human genetic information impacts drug response, and it aims to improve efficacy and reduced side effects. In this article, we provide an overview of pharmacogenetics, including pharmacokinetics (PK), pharmacodynamics (PD), gene and pathway interactions, and off-target effects. We describe methods for discovering genetic factors in drug response, including genome-wide association studies (GWAS), expression analysis, and other methods such as chemoinformatics and natural language processing (NLP). We cover the practical applications of pharmacogenomics both in the pharmaceutical industry and in a clinical setting. In drug discovery, pharmacogenomics can be used to aid lead identification, anticipate adverse events, and assist in drug repurposing efforts. Moreover, pharmacogenomic discoveries show promise as important elements of physician decision support. Finally, we consider the ethical, regulatory, and reimbursement challenges that remain for the clinical implementation of pharmacogenomics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.